Two inborn errors of coenzyme A (CoA) metabolism are responsible for distinct forms of neurodegeneration with brain iron accumulation (NBIA), a heterogeneous group of neurodegenerative diseases having as a common denominator iron accumulation mainly in the inner portion of globus pallidus. Pantothenate kinaseassociated neurodegeneration (PKAN), an autosomal recessive disorder with progressive impairment of movement, vision and cognition, is the most common form of NBIA and is caused by mutations in the pantothenate kinase 2 gene (PANK2), coding for a mitochondrial enzyme, which phosphorylates vitamin B5 in the first reaction of the CoA biosynthetic pathway. Another very rare but similar disorder, denominated CoPAN, is caused by mutations in coenzyme A synthase gene (COASY) coding for a bi-functional mitochondrial enzyme, which catalyzes the final steps of CoA biosynthesis. It still remains a mystery why dysfunctions in CoA synthesis lead to neurodegeneration and iron accumulation in specific brain regions, but it is now evident that CoA metabolism plays a crucial role in the normal functioning and metabolism of the nervous system.
| INTRODUCTION
Movement disorders (dystonia and parkinsonism), gait dysfunction, cognitive decline, retinal degeneration, and optic atrophy are, together with cerebral iron accumulation, the main distinguishing features of PKAN and COPAN, two neurodegenerative disorders associated with CoA metabolism impairment.
PKAN accounts for approximately 50% of NBIA cases and is caused by mutations in pantothenate kinase type 2 gene, while CoPAN, an extremely rare disorder, has been associated with mutations in CoA synthase (COASY) gene. Both genes code for mitochondrial proteins, and recent findings derived from cellular and animal models for PKAN and yeast model for CoPAN highlight a central role of mitochondrial metabolism in triggering the disease. In addition, CoA is a crucial factor in regulating a huge number of enzymatic reactions and biochemical pathways; thus, playing a pleiotropic role in the modulation of cellular metabolism. Reduced CoA levels have been demonstrated in PANK-deficient Drosophila fumble mutants and in mice lacking both Pank1 and Pank2 genes, while defective de novo CoA synthesis has been demonstrated in fibroblasts derived from COASY-deficient patients. Here, we will summarize knowledge about the disease mechanism that has been gained over the last ten years from the generation of different model systems and from studying patients starting from PANK2, the first identified NBIA-related gene, to the more recently discovered COASY. All this knowledge has been instrumental to develop experimental treatments for PKAN and lead to a dedicated therapeutic trial after more than 15 years from the discovery of the gene responsible for this condition.
multitude of biochemical transformations, including the TCA (tricarboxylic acid) cycle and fatty acid metabolism. CoA and acetyl-CoA levels regulate numerous biological processes, such as cell growth, cell death, autophagy, epigenetics, signal transduction, protein acetylation, and others. 2 It has been estimated that approximately 4% of cellular enzymes use it as substrate, while as cofactor it participates in more than one hundred cellular metabolic reactions. 3 The molecule consists of 3 0 -phosphoadenosine coupled through the 5 0 position of the ribose to pantothenic acid by a pyrophosphate linkage; the carboxyl end of pantothenic acid is linked through a peptidic linkage to β-mercaptoethylamine.
4
The thiol group of CoA or CoA-derived cofactors, contributed by cysteine that is selectively incorporated and decarboxylated during CoA biosynthesis, is essential to the catalytic functionality. Its absence makes CoA unable to perform its functions. 5 The majority of intracellular CoA is synthetized by a de novo, highly conserved five-step pathway, which includes: pantothenic acid (vitamin B 5 ) phosphorylation, cysteine conjugation, decarboxylation, conjugation to an adenosyl group, and phosphorylation. The five enzymes that carry out these reactions are pantothenate kinase (PANK), 4 0 -phosphopantothenoylcysteine synthetase (PPCS), 4 0 -phosphopantethenoylcysteine decarboxylase (PPCDC), phosphopantetheine adenylyltransferase (PPAT), and dephospho-CoA kinase (DPCK) 6 ( Figure 1 12 Importantly, one of the reported subjects showed iron deposition in globus pallidus (GP) and substantia nigra, suggesting that the pathophysiology of SLC25A42 deficiency could be similar to PKAN and CoPAN. 12 The intracellular CoA pool could be replenished by external CoA present in fruit fly food or cell medium. 13 It has been proposed that external CoA is cleaved by extracellular ectonucleotide pyrophosphatases (ENPPs) into 3 0 ,5 0 -ADP and 4 0 phosphopantheteine (P-PantSH). The latter represents the product of PPCDC in the de novo CoA biosynthetic pathway ( Figure 1 ) and is stable in culture medium or in serum. 13 Nevertheless, it is still not clear if PPantSH is membrane permeable in some cell types and whether dedicated PPantSH transporters exist in some systems (quoted from Ref.
8).
On the other hand, the activity of two nudix hydrolases, Nudt7 and Nudt19, controls CoA degradation into acylphosphopantetheine and 3 0 ,5 0 -ADP in liver and kidney peroxisomes.
14,15
| PANK2: PATIENTS AND MODELS
The first inborn error of CoA metabolism discovered is caused by autosomal recessive mutations in the PANK2 gene, mapping on human chromosome 20p132, which cause Pantothenate-kinase associated neurodegeneration (PKAN) (OMIM #606157). 16 PKAN presents with variable, agedependent phenotypes: the classical form presents early in childhood, usually before six years of age (mean age 3.5).
The most common presenting symptom is dystonia that classically involves the oro-mandibular region and is accompanied by impaired gait resulting from the combination of lower-limb dystonia and spasticity. Atypical PKAN tends to manifest later, in late adolescence-early adulthood (mean age 13.5). Clinically, parkinsonism mainly of an akineticrigid type is more severe than dystonia and can be accompanied by neuropsychiatric disturbances and progressive cognitive decline. Dystonia tends to affect mainly the oro-mandibular region and the tongue, causing a dysarthric speech, swallowing and feeding difficulties, sometimes being triggered or worsened by phonation and chewing. Psychiatric symptoms include personality changes, obsessive-compulsive disorder, anxiety, impulse control disorder, depression, and emotional lability. 17, 18 Both forms are characterized by iron accumulation in GP, with a peculiar brain MRI appearance referred to as the "eye of the tiger sign", consisting of bilateral pallidal hypontensity with central hyperintense signal on susceptibilityweighted imaging (SWI/T2*).
19
PANK2 is one of four human pantothenate kinase enzymes and is specifically located in the mitochondrial inter-membrane space in human 20 and mouse. 21 PANK2 catalyzes the first limiting-step in mitochondrial CoA biosynthesis ( Figure 1 ). The reason for iron accumulation in PKAN is still unknown, but it is thought to represent an epiphenomenon of the disease rather than the main culprit. MRI studies on pre-symptomatic patients with PKAN support the possibility that neuronal loss precedes iron accumulation, and that iron accumulation may be the consequence of neuronal degeneration 22 rather than the cause. Mutations in PANK2
are expected to result in defective CoA biosynthesis, which could lead to a variety of metabolic defects. A global metabolic profiling approach on plasma samples and fibroblasts derived from PKAN patients revealed defects in fatty acid metabolism characterized by reduced lipid and cholesterol biosynthesis and impaired bile acid metabolism. 23 Moreover, lipidomic analysis on red blood cells from
Italian patients affected by PKAN showed an increased number of small red blood cells together with membrane phospholipid alteration, particularly a significant increase in sphingomyelin/phosphatidylcholine and sphingomyelin/phosphatidylethanolamine ratios. The membrane structural abnormalities were associated with membrane fluidity perturbation, which could consequently alter transmembrane protein dispersion and phospholipid interaction with cytoskeleton proteins. 24 Recently, it has also been hypothesized that diminished CoA pools have injurious effects on histone and tubulin acetylation, contributing to the neurological phenotype of PKAN. 25, 26 Moreover, knockdown of PANK2 in different human cells leads to a marked induction of ferroportin mRNA, the only cellular exporter of iron, other than a decrease of ferritin and increase of transferrin receptor 1 levels. 27 Mitochondrial involvement in PKAN pathogenesis has been demonstrated by several scientific reports. Fibroblasts from PKAN patients displayed altered iron dependent oxidative status and mitochondrial iron homeostasis dysfunction, associated with mitochondrial membrane potential alteration and ROS accumulation. 28 Importantly, human-derived PKAN neurons displayed profound impairment of mitochondrial respiration and of electrophysiological properties, along with lipid peroxidation and alteration of oxidative status, mitochondrial iron-dependent biosynthetic pathway, and cytosolic iron homeostasis.
29,30
The Pank2-KO mouse model does not recapitulate the main features of the human disorder, namely movement disorder and brain iron accumulation, but displays growth reduction, retinal degeneration and male infertility due to azoospermia. 31 CoA levels in different Pank2-KO mouse tissues were measured and appeared to be within the normal range. 32 Interestingly, a significant CoA reduction was found only in the brain of Pank1/Pank2 double-KO pups, while simultaneous knockout of Pank2/Pank3 or Pank1/ Pank3 in mice lead to embryonic lethality, suggesting that, at least in mouse, the expression of other PANK isoforms may have a compensatory effect. 32 Moreover, daily injections of high doses of hopantenate (HoPan), a competitive inhibitor of all pantothenate kinases, were able to produce a severe phenotype in mice, requiring euthanasia in 5-8 days, but without evidence of iron accumulation in brain. 25, 33 Basal ganglia of Pank2-KO mice shows altered mitochondria with abnormal cristae and enlarged cisternae. 21 Isolated mitochondria from Pank2-KO animals showed significant reduction of oxygen consumption rate. 34 Finally, a neurological phenotype could be produced when knockout mice were fed with a ketogenic diet.
34
Drosophila possesses only one pantothenate kinase isoform (fumble). The dPANK/fbl hypomorphic model displays decreased levels of CoA, mitochondrial dysfunctions, increased protein oxidation, lipid dyshomeostasis, neurological impairment characterized by locomotor defects, infertility, reduced lifespan, and brain vacuolization. 35 Importantly, re-expression of the PANK2 human gene is able to rescue the eclosion rates, survival, locomotor defects, and infertility, whereas other human PANK, such as PANK3 and PANK4, can significantly rescue most fbl defects except male sterility. 36 Zebrafish possess a single ortholog of Pank2 together with three other paralogs (Pank1a, Pank1b, and Pank4).
Morpholino-mediated Pank2 down-regulation causes abnormal development of central nervous system (CNS) and vascular structures. Significant oedema in the midbrain/hindbrain ventricle and a severe perturbation of brain morphology seem to be associated with a clear loss of neural cells primarily in telencephalon, the proposed fish's brain area homologous to vertebrate pallidum. 37 
| COASY: PATIENTS AND MODELS
COASY protein-associated neurodegeneration (CoPAN) (OMIM #615643) is the second inborn error of CoA metabolism caused by mutations in COASY, a gene located on human chromosome 17q21. 38 This gene encodes for the bifunctional 4 0 -phosphopantetheine adenylyltransferase/dephospho-CoA kinase (PPAT/DPCK), also known as CoA synthase, which catalyzes the last two steps of CoA biosynthesis ( Figure 1 ). As PANK2, CoA synthase is a mitochondrial enzyme, mainly located in the mitochondrial matrix. 38, 39 This again suggests the central role of mitochondrial function in CoA metabolism-associated neurodegeneration. CoPAN is characterized by mild oro-mandibular dystonia with dysarthria, spastic-dystonic gait, severe parkinsonism, areflexia in the lower limbs, and loss of the capacity to ambulate independently. Hypointensity in the GPi or bilateral hyperintensity and swelling of caudate nucleus, putamen, and thalamus were found on patients' brain MRI. 38, 40, 41 Metabolic investigations showed increased free carnitine and decreased acylcarnitines in the patients' blood samples. 41 Patients' fibroblasts displayed significant reduction of de novo CoA and dPCoA production. Since cellular CoA was not totally ablated, this suggests the existence of an alternative, yet uncharacterized pathway for CoA biosynthesis, or the possibility that the remaining COASY aberrant protein present in fibroblasts retains some catalytic activity. 38 The yeast Saccaromices cerevisiae has the same CoA biosynthetic pathway described in mammals, catalyzed by enzymes encoded by CAB1 to CAB5 genes. 42 In yeast, as well as in E. coli, the PPAT and DPCK activities reside on different proteins encoded by CAB4 and CAB5, respectively. Interestingly, deletion of each CAB gene results in lethal phenotype, while the presence of CAB5 or COASY carrying the same mutations found in patients leads to auxotrophic phenotype for panthotenate and to reduced growth, along with CoA levels reduction to 40% compared to wild-type strain. 43 Zebrafish possess a single Coasy gene, with high level of homology to the human hortholog. The complete ablation of fish Coasy expression leads to severe alteration of development with death occurring within 72 h post fertilization. The partial down-regulation resulted in milder phenotype, characterized by generalized reduction in size and poor definition of brain structures, alteration of vasculature structure in brain and trunk, and CoA reduction in embryo extracts. 44 To date, no CoPAN mammalian animal model has been described.
| THERAPEUTIC APPROACHES
Currently, treatment for inborn error of CoA metabolism and, in general, for NBIA disorders remains symptomatic. Most treatments are aimed at reducing dystonia and parkinsonism, being the main source of patients' disability. These include dopaminergic drugs, anticholinergics, tetrabenazine, baclofen, botulinum toxin, and other drugs; however, these treatments do not modify disease progression. In about 30% of cases some benefits in alleviating movement disorders, especially dystonia, have been obtained by surgical procedures including thalamotomy, pallidotomy or deep brain stimulation (DBS), but again without altering long-term outcome. 19 Iron-chelating agent deferiprone has also been pro- Moreover, the most promising approach to treat inborn error of CoA metabolism is the application of CoA or its precursors (Figure 1) . Pantethine, the dimeric form of pantetheine, rescues the phenotype of Drosophila 46 and mouse 34 PKAN models. However, this does not produce benefit in humans because pantethine is highly unstable in serum and is rapidly converted into vitamin B5 and cysteamine, rather than into CoA, by a class of enzymes called vanins. 47 On the contrary, Srinivasan et al 13 hypothesized
that application of 4 0 -phosphopantetheine (P-PantSH) may be the clue, since it is stable in serum, taken up by cells via passive diffusion, and is then enzymatically converted back to CoA intracellularly. Recently, P-PantSAc, an acetylated derivative of P-PantSH, (TM-1803, TM3Therapeutics, http://www.tm3therapeutics.com) has shown very promising efficacy in cell lines and animal models, and has been granted an orphan drug designation by the European Medicines Agency. It has been demonstrated that this compound is stable in serum, has low toxicity on human and Drosophila cells, rescues HoPan-induced Drosophila larval lethality, and reverts the clinical and biochemical abnormal phenotypes induced by HoPan in mice, fully restoring CoA levels. 25 Moreover, P-PantSAc may have advantages because the synthesis procedure allows for linkage of other acyl moieties to P-PantSH in order to convert P-PantSH into various acyl derivatives. 25 Another compound that has been granted an orphan drug designation from both the FDA and European Medicine Agency is fosmetpantotenate (RE-024, Retrophin, http:// www.retrophin.com), a phosphopantothenate derivative. An open-label, uncontrolled, 12-month treatment with fosmetpantotenate of a single patient with a late-onset, moderately severe, and slowly progressive form of PKAN, resulted in the improvement in all clinical parameters including the Unified Parkinson's Disease Rating Scale (UPDRS), BarryAlbright Dystonia Scale, and EuroQol five-dimensional three-level (EQ-5D-3 L) scale. 48 CoA itself has been proposed to be efficacious in the treatment of inborn error of CoA metabolism 13 and Orellana and collaborators (2016) demonstrated that CoA administration to iPSCs-derived patients' neurons restores PKAN neuron functionality, inhibits neuronal cell death, prevents the development of harmful ROS, and rescues heme biosynthesis and respiratory activity, establishing a strong proof of principle for the use of this compound as a therapeutic agent. These findings are corroborated by in vivo data. External CoA was able to revert HoPan-induced Drosophila larval lethality, 13 and fully prevented the development of the PKAN zebrafish abnormal phenotype. 37 Finally, CoA administration to the HoPan-treated mouse model fully restored intracellular CoA levels, reverting the clinical and biochemical abnormal phenotypes. 25 Recently, the Oregon Health & Science University announced CoA-Z (http://nbiacure.org), a new compound that could be used for the treatment of PKAN, although no data has been published yet.
| CONCLUSIONS AND FUTURE PERSPECTIVES
CoA is an essential and universally utilized cofactor that works as the major acyl group carrier in all cells. This small molecule plays a central role in hundreds of metabolic reactions involved in the metabolism of fatty acids, carbohydrates, amino acids, and ketone bodies. Tissue CoA levels are tightly regulated and vary in response to different conditions. The majority of intracellular CoA is synthetized by a de novo biosynthetic pathway from pantothenate (vitamin B5). Although in some plants and bacteria, including E. coli, pantothenate can be synthesized de novo, in humans and most living organisms it is an essential vitamin that must be taken from diet. PKAN and CoPAN are two forms of NBIA that are associated with mutations in PANK2 and COASY, i.e., genes that code for enzymes catalyzing the first and last steps of the CoA biosynthetic pathway, respectively. Despite that evidence suggests iron deposition might be secondary to a major metabolic impairment of neural cells, it remains unexplained why mutations in the enzymes involved in the CoA biosynthetic pathway cause neurodegeneration. It has been proposed that altered lipid metabolism, due to limited CoA availability, represents a potential disease mechanism, affecting synthesis and remodeling of cellular membranes. This is evident in mitochondria, where alteration of cristae structure is a common feature in some NBIA syndromes. Nevertheless, evidence is insufficient to explain all the clinical and biochemical features of PKAN and CoPAN. Other mechanisms, such as impairment of proteins acetylation and epigenetic homeostasis, could contribute to the pathogenesis of the disease. More recently, a fascinating hypothesis connected levels of transferrin receptor palmitoilation with altered iron handling in fibroblasts derived from patients carrying mutations in PANK2, PLA2G6, COASY, C19ORF12, and FA2H. 49 Further insights into the pathophysiology will hopefully allow the development of tailored mechanistic therapies in the future. Despite that present therapeutic approaches are limited to symptomatic treatments, very recently novel compounds have been developed and proposed as promising candidates for pharmacological approaches. Setting up large-scale clinical trials for these molecules will be the upcoming challenge to cure this group of rare degenerative disorders in the near future.
ACKNOWLEDGMENTS
The support of Telethon GGP16234 to VT and of Mariani Foundation of Milan is gratefully acknowledged.
AUTHOR' S CONTRIBUTION
IDM: Drafting of the manuscript; VT: Conception and design; MC revising the clinical description; IDM, MC and VT: Revising of the manuscript.
COMPLIANCE WITH ETHICS GUIDELINES CONFLICT OF INTEREST
Ivano Di Meo declares that he has no conflict of interest. Miryam Carecchio declares she has no conflict of interest. Valeria Tiranti declares that she has no conflict of interest.
ORCID
Valeria Tiranti https://orcid.org/0000-0002-3584-7338
